Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire.
The FTC’s unconditional clearance of the move “is another significant milestone in the transaction process,” the firm said.
Takeda announced plans to buy Shire in a deal valued at around £46 billion back in May, ranking as one of the industry’s biggest.
“Shire’s highly complementary product portfolio and pipeline, as well as experienced employees, will accelerate our transformation for a stronger Takeda,” said Takeda’s chief executive Christophe Weber, explaining the move.
“Together, we will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies.”
The acquisition remains subject to a number of conditions, including receipt of other regulatory clearances and approval by the shareholders of both companies.